AbbVie’s Allergan Aesthetics reports higher facial satisfaction in GLP‑1 users
AbbVie’s Allergan Aesthetics division presented results from two Phase 4 studies showing that adults on GLP‑1 weight‑loss drugs reported higher satisfaction with facial appearance after receiving injectable fillers and Botox. The Harmony In Diversity study involved 30 patients and recorded a 42.4‑point gain on a 100‑point questionnaire, while the interim Halo analysis of 25 patients showed a 39.6‑point gain after three months. Both studies were presented at the American Society for Dermatologic Surgery’s annual meeting in San Diego.
Why it matters
The company notes the findings could expand demand for its Botox and filler products among GLP‑1 users, a growing patient segment. Investors may view the data as a catalyst for sales growth in the aesthetics portfolio.
Key facts
- 1The Harmony In Diversity study enrolled 30 patients who received hyaluronic acid fillers, Botox and skincare treatments. tradingview.com
- 2Participants in the Harmony In Diversity study reported an average 42.4‑point improvement in facial appearance satisfaction on a 100‑point questionnaire. tradingview.com
- 3The interim Halo study included 25 patients who received facial filler treatment. tradingview.com
- 4Halo participants showed a 39.6‑point improvement in facial satisfaction after three months. tradingview.com
- 5Both studies were presented at the American Society for Dermatologic Surgery’s annual meeting in San Diego. tradingview.com
- 6The studies had no untreated control group and enrolled adults on stable GLP‑1 doses. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.